Lakefront Biotherapeutics (LKFT) Stock Forecast & Price Target

Lakefront Biotherapeutics is attractive because gamgertamig appears to have a differentiated BCMA/CD3 profile with rapid, deep B-cell depletion, durable remissions, and a lower-risk safety profile than CAR-T, while more than 60 autoimmune cytopenia patients already provide an early efficacy and tolerability signal. The company’s outlook is further strengthened by a strong balance sheet, with an expected €2B in cash by end-2026, projected cash flow positivity by YE26 excluding Ouro, and roughly €400M of spend remaining before first approval, which helps support downside protection and future business-development flexibility. Management’s 2026 dose-escalation readout and 2027 registrational programs in autoimmune cytopenias could de-risk the story further, and if adoption expands across additional indications, royalties could eventually become meaningful.

Lakefront Biotherapeutics is viewed negatively because its valuation depends heavily on adding competitive assets and successfully advancing a fragile pipeline, while GLPG3667 has already failed in SLE at both the 32-week primary endpoint and 48-week secondary endpoint. The company’s own disclosed downside cases imply share weakness if GLPG3667 disappoints or is not out-licensed, and if competitive pressures reduce the commercial opportunity for any new assets. With no further development of GLPG3667 in lupus and no expected data updates on the Ouro preclinical assets until 2027+, the pipeline remains exposed to execution risk, valuation uncertainty, and unknown toxicity concerns.